Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Bayer
Boehringer Ingelheim
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OncoC4, Inc.
Genmab
USWM, LLC (dba US WorldMeds)
Pfizer
Pfizer
Mayo Clinic
Hoffmann-La Roche
Erasca, Inc.
M.D. Anderson Cancer Center
University of California, Davis
City of Hope Medical Center
Novartis
ImmunityBio, Inc.
AbbVie
University Health Network, Toronto
AgonOx, Inc.
Novartis
Pierre Fabre Medicament
Inhibrx Biosciences, Inc
National Cancer Institute (NCI)
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
University of Pittsburgh
Asher Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc.
Milton S. Hershey Medical Center
TILT Biotherapeutics Ltd.
Providence Health & Services
Oslo University Hospital
OncoC4, Inc.
Theratechnologies
SOLTI Breast Cancer Research Group
UNICANCER
Checkpoint Therapeutics, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
RemeGen Co., Ltd.
NantBioScience, Inc.
iTeos Therapeutics
Adaptimmune